2030’s Biotech, According to Future Nobel Laureates
A reflection on biotech after attending Canada’s Gairdner Gala (trends, core questions & insights)
--
In October 2022, I had the privilege of attending the Canada Gairdner Award lectures and exclusive gala.
The Gairdner foundation honours biomedical research from around the world. This year’s winners included the inventors of the COVID-19 mRNA vaccine. One-quarter of the winners eventually earn a Nobel Prize. And regardless, all of their work has an expansive impact on medicine and science.
My experience learning from ingenious scientific conversations was like, what I imagine, children feel when they see their cartoon heroes at Disney world. Magic. Unbelievable. Fireworks.
I am thankful to the Morehead-Cain Foundation for funding this trip and to The Knowledge Society for getting me an invite to attend!
The experience was a turning point for me. It clarified the direction of my education: to the cutting edge of biochemical inventions. I’m thankful for the opportunity to get a sneak peek into the real world of science.
I’d like to take my reflections on this experience forward — to the questions and concepts at the brink of scientific disruption.
In this post I’ll highlight some of the big-picture areas of biotech I’m excited about and the molecules and tactics I head through Gairdner’s programming that profoundly piqued my interest! ❤️❤️
Part 1: 3 Lessons from A Big Picture Framework for Biotech
How will we…
Cure cancer? Make an HIV vaccine? Reverse fatal genetic conditions like cystic fibrosis, sickle-cell and Huntington’s? Distribute medical care in low-resource communities? Build new treatments for heart failure, the #1 cause…
